Articles, Neurobiology of Disease
Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy
Tomas Borgegård, Susanne Gustavsson, Charlotte Nilsson, Santiago Parpal, Rebecka Klintenberg, Anna-Lena Berg, Susanne Rosqvist, Lutgarde Serneels, Samuel Svensson, Fredrik Olsson, Shaobo Jin, Hongmei Yan, Johanna Wanngren, Anders Jureus, Anna Ridderstad-Wollberg, Patrik Wollberg, Kenneth Stockling, Helena Karlström, Åsa Malmberg, Johan Lund, Per I. Arvidsson, Bart De Strooper, Urban Lendahl and Johan Lundkvist
Journal of Neuroscience 28 November 2012, 32 (48) 17297-17305; https://doi.org/10.1523/JNEUROSCI.1451-12.2012
Tomas Borgegård
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Susanne Gustavsson
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Charlotte Nilsson
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Santiago Parpal
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Rebecka Klintenberg
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Anna-Lena Berg
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Susanne Rosqvist
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Lutgarde Serneels
2Center for Human Genetics and Leuven Institute for Neurodegenerative Disorders (LIND), University of Leuven, 3000 Leuven Belgium,
3VIB Center for the Biology of Disease (VIB11), 3000 Leuven, Belgium,
Samuel Svensson
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
8Department of Pharmacology, Linköping University, Sweden, and
9Alzacure Foundation, Korphoppsgatan 33, SE-12064 Stockholm, Sweden
Fredrik Olsson
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Shaobo Jin
4Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden,
Hongmei Yan
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Johanna Wanngren
5Department of Neurobiology, Caring Sciences and Society, KI-Alzheimer Disease Research Center, Karolinska Institutet, Novum, SE-141 86 Stockholm, Sweden,
Anders Jureus
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Anna Ridderstad-Wollberg
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Patrik Wollberg
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Kenneth Stockling
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Helena Karlström
5Department of Neurobiology, Caring Sciences and Society, KI-Alzheimer Disease Research Center, Karolinska Institutet, Novum, SE-141 86 Stockholm, Sweden,
Åsa Malmberg
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Johan Lund
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
Per I. Arvidsson
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
6Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala Biomedical Centre, Uppsala University, SE-751 23 Uppsala, Sweden,
7School of Pharmacy and Pharmacology, Westville Campus, University of KwaZulu-Natal, Durban 4000, South Africa,
Bart De Strooper
2Center for Human Genetics and Leuven Institute for Neurodegenerative Disorders (LIND), University of Leuven, 3000 Leuven Belgium,
3VIB Center for the Biology of Disease (VIB11), 3000 Leuven, Belgium,
Urban Lendahl
4Department of Cell and Molecular Biology, Karolinska Institute, SE-171 77 Stockholm, Sweden,
Johan Lundkvist
1AstraZeneca, CNS and Pain Innovative Medicines, SE-15185 Södertälje, Sweden,
5Department of Neurobiology, Caring Sciences and Society, KI-Alzheimer Disease Research Center, Karolinska Institutet, Novum, SE-141 86 Stockholm, Sweden,
9Alzacure Foundation, Korphoppsgatan 33, SE-12064 Stockholm, Sweden
Published eLetters
Guidelines
As a forum for professional feedback, submissions of letters are open to all. You do not need to be a subscriber. To avoid redundancy, we urge you to read other people's letters before submitting your own. Name, current appointment, place of work, and email address are required to send a letter, and will be published with your review. We also require that you declare any competing financial interests. Unprofessional submissions will not be considered or responded to.
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Neuroscience
Vol. 32, Issue 48
28 Nov 2012
Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy
Tomas Borgegård, Susanne Gustavsson, Charlotte Nilsson, Santiago Parpal, Rebecka Klintenberg, Anna-Lena Berg, Susanne Rosqvist, Lutgarde Serneels, Samuel Svensson, Fredrik Olsson, Shaobo Jin, Hongmei Yan, Johanna Wanngren, Anders Jureus, Anna Ridderstad-Wollberg, Patrik Wollberg, Kenneth Stockling, Helena Karlström, Åsa Malmberg, Johan Lund, Per I. Arvidsson, Bart De Strooper, Urban Lendahl, Johan Lundkvist
Journal of Neuroscience 28 November 2012, 32 (48) 17297-17305; DOI: 10.1523/JNEUROSCI.1451-12.2012
Alzheimer's Disease: Presenilin 2-Sparing γ-Secretase Inhibition Is a Tolerable Aβ Peptide-Lowering Strategy
Tomas Borgegård, Susanne Gustavsson, Charlotte Nilsson, Santiago Parpal, Rebecka Klintenberg, Anna-Lena Berg, Susanne Rosqvist, Lutgarde Serneels, Samuel Svensson, Fredrik Olsson, Shaobo Jin, Hongmei Yan, Johanna Wanngren, Anders Jureus, Anna Ridderstad-Wollberg, Patrik Wollberg, Kenneth Stockling, Helena Karlström, Åsa Malmberg, Johan Lund, Per I. Arvidsson, Bart De Strooper, Urban Lendahl, Johan Lundkvist
Journal of Neuroscience 28 November 2012, 32 (48) 17297-17305; DOI: 10.1523/JNEUROSCI.1451-12.2012
Jump to section
Responses to this article
Jump to comment:
No eLetters have been published for this article.